Myeloproliferative disordersMURRAY, Jim.Clinical medicine. 2005, Vol 5, Num 4, pp 328-332, issn 1470-2118, 5 p.Article

Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with timeBAKER, R. I; MANOHARAN, A.European journal of haematology. 1988, Vol 40, Num 3, pp 267-272, issn 0902-4441Article

Transient myeloproliferative disorderMOIZ, Bushra; SHAFLQ, Maria.Blood. 2012, Vol 120, Num 24, issn 0006-4971, p. 4672Article

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseAGARWAL, Anupriya; BUMM, Thomas G. P; DEININGER, Michael W et al.Blood. 2008, Vol 112, Num 5, pp 1960-1970, issn 0006-4971, 11 p.Article

Genetics of myeloid malignancies : Pathogenetic and clinical implicationsFROHLING, Stefan; SCHOLL, Claudia; GILILAND, D. Gary et al.Journal of clinical oncology. 2005, Vol 23, Num 26, pp 6285-6295, issn 0732-183X, 11 p.Article

Myeloproliferative neoplasmsPUBLICOVER, Amy; MEDD, Patrick.Clinical medicine. 2013, Vol 13, Num 2, pp 188-192, issn 1470-2118, 5 p.Article

Syndromes myéloprolifératifs Philadelphie-négatifsKILADJIAN, Jean-Jacques.Hématologie (Montrouge). 2007, Vol 13, pp 55-58, issn 1264-7527, 4 p., NS1Conference Paper

Mini Symposium sur les Syndromes MyéloprolifératifsBRIERE, J.Pathologie et biologie. 2001, Vol 49, Num 2, pp 138-183, issn 0369-8114Conference Proceedings

Role of Additional Novel Therapies in Myeloproliferative NeoplasmsFISKUS, Warren; GANGULY, Siddhartha; KAMBHAMPATI, Suman et al.Hematology/oncology clinics of North America. 2012, Vol 26, Num 5, issn 0889-8588, vii, 959-980 [22 p.]Article

Treatment paradigms in the management of myeloproliferative disordersFRUCHTMAN, Steven M.Seminars in hematology. 2004, Vol 41, Num 2, pp 18-22, issn 0037-1963, 5 p., SUP3Article

Histomorphologische Befunde am Knochenmark bei chronischen myeloproliferativen Erkrankungen = Chronic myeloproliferative disorders: histomorphological findings of the bone marrowTHIELE, J; FISCHER, R.H + G. Zeitschrift für Hautkrankheiten. 1989, Vol 64, Num 10, pp 903-912, issn 0301-0481, 6 p.Article

Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid NeoplasmsOGAWA, Seishi; SHIH, Lee-Yung; SUZUKI, Takahiro et al.Clinical cancer research (Print). 2010, Vol 16, Num 15, pp 3825-3831, issn 1078-0432, 7 p.Article

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsQUINTAS-CARDAMA, Alfonso; VADDI, Kris; RUPAR, Mark et al.Blood. 2010, Vol 115, Num 15, pp 3109-3117, issn 0006-4971, 9 p.Article

Bleeding diathesis coincident with chronic myelomonocytic leukaemiaHEARD, S. E; REVELL, P; HOLLAND, L. J et al.Journal of clinical pathology. 1991, Vol 44, Num 11, pp 956-958, issn 0021-9746Article

The treatment of essential thrombocythaemia with radioactive phosphorusWAGNER, S; WAXMAN, J; SIKORA, K et al.Clinical radiology. 1989, Vol 40, Num 2, pp 190-192, issn 0009-9260Article

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsSCORE, Joannah; HIDALGO-CURTIS, Claire; CHASE, Andrew et al.Blood. 2012, Vol 119, Num 5, pp 1208-1213, issn 0006-4971, 6 p.Article

Competing cell clones in myeloproliferative neoplasmAL-KALI, Aref; VERSTOVSEK, Srdan; KANTARJIAN, Hagop et al.Blood. 2010, Vol 116, Num 23, pp 5074-5075, issn 0006-4971, 2 p.Article

Myeloproliferative Disorders and the Hyperviscosity SyndromeADAMS, Bruce D; BAKER, Russell; LOPEZ, J. Abraham et al.Hematology/oncology clinics of North America. 2010, Vol 24, Num 3, issn 0889-8588, viii, 585-602 [28 p.]Article

Myeloproliferative Disorders and the Hyperviscosity SyndromeADAMS, Bruce D; BAKER, Russell; LOPEZ, J. Abraham et al.Emergency medicine clinics of North America. 2009, Vol 27, Num 3, issn 0733-8627, vi, 459-476 [19 p.]Article

Hematopathologic findings in chronic idiopathic myelofibrosisTHIELE, Juergen; KVASNICKA, Hans M.Seminars in oncology. 2005, Vol 32, Num 4, pp 380-394, issn 0093-7754, 15 p.Article

CML: Molecular Mechanisms & Therapeutic StrategiesARLINGHAUS, Ralph B.Oncogene (Basingstoke). 2002, Vol 21, Num 56, issn 0950-9232, 141 p., NS7Serial Issue

Hematological causes of venous thrombosis in young people : high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosisTEOFILI, L; DE STEFANO, V; LEONE, G et al.Thrombosis and haemostasis. 1992, Vol 67, Num 3, pp 297-301, issn 0340-6245Article

Intérêt clinique du dosage de l'érythropoiétine dans les syndromes myéloprolifératifs = Clinical value of erythropoïetin assays in myeloproliferative syndromesSCHLAGETER, M. H; TOUBERT, M. E; PODGORNIAK, M. P et al.La Presse médicale (1983). 1989, Vol 18, Num 40, issn 0755-4982, 1978Article

Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia: a study of 34 casesBRENNER, B; NAGLER, A; TATARSKY, I et al.Archives of internal medicine (1960). 1988, Vol 148, Num 11, pp 2501-2505, issn 0003-9926Article

DNMT3A mutations in myeloproliferative neoplasmsSTEGELMANN, F; BULLINGER, L; SCHLENK, R. F et al.Leukemia. 2011, Vol 25, Num 7, pp 1217-1219, issn 0887-6924, 3 p.Article